The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial
Open accessAbstract
CONTEXT: The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation. OBJECTIVE: To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007. SETTING: Psychosis detection unit of a large public hospital in Vienna, Austria. PARTICIPANTS: Eighty-one individuals at ultra-high risk of psychotic disorder. INTERVENTIONS: A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months. MAIN OUTCOME MEASURES: The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition. RESULTS: Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups. CONCLUSIONS: Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only two studies had an overall low risk of bias 33,79 ; five had unclear risk [72][73][74][75][76] , and nine had high risk 30,31,36,37,39,41,77,78,81 .”
From Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis (2018) · cites this paper as [33]
In the citing paper
“Earlier studies that dominated the conclusions of some previous meta-analyses (e.g., the omega-3 trial 33 ) were likely false positives.”
From Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis (2018) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003814 · Cited by 2,343
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
The Family History Method Using Diagnostic Criteria
Andreasen, N. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220111013 · Cited by 1,903
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
Research works printed but not linked: 1
- First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
Cited by
Sorted by citations
Items 101–200 of 895
Martinat, M., Rossitto, M., Miceli, M. D., & Layé, S. (2021) · Nutrients · doi:10.3390/nu13041185 · Cited by 152
Social Cognition in Individuals at Ultra-High Risk for Psychosis: A Meta-Analysis
van Donkersgoed, R. J. M., Wunderink, L., Nieboer, R. M., Aleman, A., & Pijnenborg, G. H. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141075 · Cited by 138
Attenuated Psychosis Syndrome: Ready for DSM-5.1?
Fusar‐Poli, P., Carpenter, W. T., Woods, S. W., & McGlashan, T. H. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153645 · Cited by 136
Koutsouleris, N., Davatzikos, C. A., Ronald Bottlender, A., Patschurek‐Kliche, K., Scheuerecker, J., Decker, P., Christian Gaser, B., Möller, H., & Meisenzahl, E. M. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr037 · Cited by 132
Hoen, W. P., Lijmer, J. G., Durán, M., Wanders, R. J. A., van Beveren, N. J. M., & de Haan, L. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.041 · Cited by 132
Assies, J., Mocking, R. J. T., Lok, A., Ruhé, H. G., Pouwer, F., & Schene, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12265 · Cited by 134
Cuénod, M., Steullet, P., Cabungcal, J.-H., Dwir, D., Khadimallah, I., Klauser, P., Conus, P., & Kim, Q. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01374-w · Cited by 134
The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome
Woods, S. W., Walsh, B. C., Saksa, J. R., & McGlashan, T. H. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.012 · Cited by 130
The psychosis risk syndrome and its proposed inclusion in the DSM-V: A risk–benefit analysis
Corcoran, C. M., First, M. B., & Cornblatt, B. A. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.018 · Cited by 129
McEvoy, J., Baillie, R. A., Zhu, H., Buckley, P., Keshavan, M. S., Nasrallah, H. A., Dougherty, G. G., Yao, J. K., & Kaddurah-Daouk, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068717 · Cited by 127
Prediction and prevention of schizophrenia: what has been achieved and where to go next?
Klosterkötter, J., Schultze‐Lutter, F., Bechdolf, A., & Ruhrmann, S. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00044.x · Cited by 127
Berger, M., Smesny, S., Kim, S.-W., Davey, C. G., Rice, S., Sarnyai, Z., Schlögelhofer, M., Schäfer, M. R., Berk, M., McGorry, P. D., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.190 · Cited by 133
Self-citationOmega-3 polyunsaturated fatty acids and cognition throughout the lifespan: A review
Karr, J. E., Alexander, J. E., & Winningham, R. G. (2011) · Nutritional Neuroscience · doi:10.1179/1476830511y.0000000012 · Cited by 133
Oxidative stress in schizophrenia - focusing on the main markers.
Ciobica, A. S., Pădurariu, M., Dobrin, I., Ștefănescu, C., & Dobrin, R. (2011) · PubMed · Cited by 124
Agostoni, C. V., Nobile, M., Ciappolino, V., Delvecchio, G., Tesei, A., Turolo, S., Crippa, A., Mazzocchi, A., Altamura, C. A., & Brambilla, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122608 · Cited by 138
Mongan, D., Ramesar, M., Föcking, M., Cannon, M., & Cotter, D. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.12859 · Cited by 123
The Role of Essential Fatty Acids in Human Health
Glick, N. R., & Fischer, M. H. (2013) · Journal of Evidence-Based Complementary & Alternative Medicine · doi:10.1177/2156587213488788 · Cited by 124
van der Kemp, W. J. M., Klomp, D. W. J., Kahn, R. S., Luijten, P. R., & Pol, H. E. H. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.014 · Cited by 119
McGorry, P. D. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.016 · Cited by 119
Self-citationPawełczyk, T., Grancow-Grabka, M., Kotlicka‐Antczak, M., Trafalska, E., & Pawełczyk, A. M. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.11.013 · Cited by 117
Broad-spectrum micronutrient formulas for the treatment of psychiatric symptoms: a systematic review
Rucklidge, J. J., & Kaplan, B. J. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.143 · Cited by 116
Omega-3 Fatty Acid and Nutrient Deficits in Adverse Neurodevelopment and Childhood Behaviors
Gow, R. V., & Hibbeln, J. R. (2014) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2014.02.002 · Cited by 125
Sinn, N., Milte, C., & Howe, P. R. C. (2010) · Nutrients · doi:10.3390/nu2020128 · Cited by 115
Targeting of NMDA receptors in new treatments for schizophrenia
Hashimoto, K. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.934225 · Cited by 117
Nagai, T., Tada, M., Kirihara, K., Araki, T., Jinde, S., & Kasai, K. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00115 · Cited by 115
Internet-Based, Randomized, Controlled Trial of Omega-3 Fatty Acids for Hyperactivity in Autism
Bent, S., Hendren, R. L., Zandi, T., Law, K., Choi, J., Widjaja, F., Kalb, L. G., Nestle, J., & Law, P. A. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.01.018 · Cited by 127
What drives poor functioning in the at-risk mental state? A systematic review
Cotter, J., Drake, R., Bucci, S., Firth, J., Edge, D., & Yung, A. R. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.09.012 · Cited by 111
Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
Fusar-Poli, P., Davies, C., Solmi, M., Brondino, N., De Micheli, A., Kotlicka-Antczak, M., Shin, J. I., & Radua, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00764 · Cited by 108
Pharmacological interventions for people with borderline personality disorder
Stoffers‐Winterling, J., Storebø, O. J., Ribeiro, J. P., Kongerslev, M., Vӧllm, B., Mattivi, J. T., Faltinsen, E. G., Todorovac, A., Jørgensen, M. S., Edemann-Callesen, H., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012956.pub2 · Cited by 128
Bondi, C. O., Taha, A. Y., Tock, J., Totah, N. K. B., Cheon, Y., Torres, G. E., Rapoport, S. I., & Moghaddam, B. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.007 · Cited by 117
N-3 polyunsaturated fatty acids in animal models with neuroinflammation: An update
Trépanier, M., Hopperton, K. E., Orr, S. K., & Bazinet, R. P. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.045 · Cited by 114
Cooper, R. E., Tye, C., Kuntsi, J., Vassos, E., & Asherson, P. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115587958 · Cited by 117
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
McNamara, R. K., & Lotrich, F. E. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.98 · Cited by 112
Davies, C., Radua, J., Cipriani, A., Stahl, D., Provenzani, U., McGuire, P., & Fusar-Poli, P. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00187 · Cited by 107
A review of anti-inflammatory agents for symptoms of schizophrenia
Keller, W. R., Kum, L. M., Wehring, H. J., Koola, M. M., Buchanan, R. W., & Kelly, D. L. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112467089 · Cited by 111
Wood, S. J., Yung, A. R., McGorry, P. D., & Pantelis, C. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.05.034 · Cited by 110
Self-citationAltered fatty acid concentrations in prefrontal cortex of schizophrenic patients
Taha, A. Y., Cheon, Y., Ma, K., Rapoport, S. I., & Rao, J. S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.016 · Cited by 105
Carney, R., Cotter, J., Bradshaw, T., Firth, J., & Yung, A. R. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.010 · Cited by 104
Therapeutic use of omega-3 fatty acids in bipolar disorder
Balanzá‐Martínez, V., Fries, G. R., Colpo, G. D., Silveira, P. P., Portella, A. K., Tabarés‐Seisdedos, R., & Kapczinski, F. P. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.42 · Cited by 111
Interventions for prodromal stage of psychosis
Kuharić, D. B., Kekin, I., Hew, J., Kuzman, M. R., & Puljak, L. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012236.pub2 · Cited by 116
Nagai, T., Tada, M., Kirihara, K., Yahata, N., Hashimoto, R., Araki, T., & Kasai, K. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.08.005 · Cited by 102
Thermenos, H. W., Keshavan, M. S., Juelich, R. J., Molokotos, E. K., Whitfield, S., Brent, B., Makris, N., & Seidman, L. J. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32170 · Cited by 105
Francey, S. M., Nelson, B., Thompson, A. D., Parker, A. G., Kerr, M., Macneil, C. A., Fraser, R., Hughes, F., Crisp, K., Harrigan, S., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1071 · Cited by 102
Self-citationChoi, K., Wykes, T., & Kurtz, M. M. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.107359 · Cited by 99
Should Attenuated Psychosis Syndrome Be a DSM-5 Diagnosis?
Carpenter, W. T., & van Os, J. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10121816 · Cited by 99
Kuah, M., Jaya-Ram, A., & Shu‐Chien, A. C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.012 · Cited by 98
A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia
Bentsen, H., Osnes, K., Refsum, H., Solberg, D. K., & Bøhmer, T. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.110 · Cited by 97
Chen, C. T., Liu, Z., & Bazinet, R. P. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07116.x · Cited by 97
Whither the attenuated psychosis syndrome?
Yung, A., Woods, S., Ruhrmann, S., Addington, J., Schultze-Lutter, F., Cornblatt, B., Amminger, G., Bechdolf, A., Birchwood, M., Borgwardt, S., et al. (2012) · Schizophrenia bulletin · doi:10.1093/schbul/sbs108 · Cited by 98
Self-citationFond, G. B., d’Albis, M.-A., Jamain, S., Tamouza, R., Arango, C., Fleischhacker, W. W., Glenthoj, B. Y., Leweke, F. M., Lewis, S. W., McGuire, P. K., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv002 · Cited by 99
The Ultra-High Risk Concept—A Review
Yung, A. R., & Nelson, B. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305800103 · Cited by 103
Basak, S., Mallick, R., Banerjee, A., Pathak, S., & Duttaroy, A. K. (2021) · Nutrients · doi:10.3390/nu13062061 · Cited by 92
The impact of lipid polyunsaturation on the physical and mechanical properties of lipid membranes
Baccouch, R., Shi, Y., Vernay, E., Mathelié‐Guinlet, M., Taib-Maamar, N., Villette, S., Feuillie, C., Rascol, E., Nuss, P., Lecomte, S., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2022.184084 · Cited by 93
Vitamin D deficiency in first episode psychosis: A case–control study
Crews, M., Lally, J., Gardner-Sood, P., Howes, O. D., Bonaccorso, S., Smith, S. M., Murray, R. M., Forti, M. D., & Gaughran, F. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.08.036 · Cited by 93
Schubert, K. O., Föcking, M., Prehn, J. H. M., & Cotter, D. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.123 · Cited by 91
FABP7 expression in normal and stab-injured brain cortex and its role in astrocyte proliferation
Sharifi, K., Morihiro, Y., Maekawa, M., Yasumoto, Y., Hoshi, H., Adachi, Y., Sawada, T., Tokuda, N., Kondo, H., Yoshikawa, T., et al. (2011) · Histochemistry and Cell Biology · doi:10.1007/s00418-011-0865-4 · Cited by 91
Anti-inflammatory treatment in schizophrenia
Müller, N., Myint, A.-M., Krause, D., Weidinger, E., & Schwarz, M. J. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.008 · Cited by 89
Bos, D. J., van Montfort, S. J. T., Oranje, B., Durston, S., & Smeets, P. A. M. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.031 · Cited by 99
Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms
Hsu, M., Huang, Y. S., & Ouyang, W. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01337-0 · Cited by 88
McNamara, R. K. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i1.15 · Cited by 88
Progress and Future Directions in Research on the Psychosis Prodrome
Woodberry, K. A., Shapiro, D. I., Bryant, C., & Seidman, L. J. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000109 · Cited by 87
Müller, N., Myint, A.-M., & Schwarz, M. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-398314-5.00003-9 · Cited by 86
Uher, R., Cumby, J., MacKenzie, L. E., Morash-Conway, J., Glover, J. M., Aylott, A., Propper, L., Abidi, S., Bagnell, A. L., Pavlová, B., et al. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0344-2 · Cited by 89
Mitra, S., Natarajan, R., Ziedonis, D. M., & Fan, X. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.005 · Cited by 87
Should a “Risk Syndrome for Psychosis” be included in the DSMV?
Yung, A. R., Nelson, B., Thompson, A. D., & Wood, S. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.017 · Cited by 85
Genetic risk prediction and neurobiological understanding of alcoholism
Levey, D. F., Le-Niculescu, H., Frank, J., Ayalew, M., Jain, N., Kirlin, B., Learman, R., Winiger, E., Rodd, Z. A., Shekhar, A., et al. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.29 · Cited by 85
Jones, H. J., Borges, M. C., Carnegie, R., Mongan, D., Rogers, P. J., Lewis, S. J., Thompson, A. D., & Zammit, S. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00286-8 · Cited by 84
Mismatch negativity (MMN) deficiency: A break-through biomarker in predicting psychosis onset
Näätänen, R., Shiga, T., Asano, S., & Yabe, H. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2014.12.012 · Cited by 82
The role of anti-inflammatory treatment in psychiatric disorders.
Müller, N. (2013) · PubMed · Cited by 82
Du, Y., Chen, L., Li, X.-S., Li, X., Xu, X., Tai, S., Yang, G.-L., Tang, Q., Liu, H., Liu, S., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa166 · Cited by 82
Systems biology strategies to study lipidomes in health and disease
Hyötyläinen, T., & Orešič, M. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.06.001 · Cited by 83
White matter development in the early stages of psychosis
Peters, B. D., & Karlsgodt, K. H. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.05.021 · Cited by 79
Devoe, D. J. A., Peterson, A. M., & Addington, J. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx139 · Cited by 82
Lin, C., & Lane, H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00093 · Cited by 85
Smesny, S., Milleit, B., Hipler, U. ‐., Milleit, C., Schäfer, M. R., Klier, C. M., Holub, M., Holzer, I., Berger, G. E., Otto, M., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.7 · Cited by 79
Self-citationPreventative Strategies for Early-Onset Bipolar Disorder
McNamara, R. K., Nandagopal, J. J., Strakowski, S. M., & DelBello, M. P. (2010) · CNS Drugs · doi:10.2165/11539700-000000000-00000 · Cited by 82
Devoe, D. J. A., Farris, M. S., Townes, P., & Addington, J. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12677 · Cited by 86
Gender and duration of untreated psychosis: a systematic review and meta‐analysis
Cascio, M. T., Cella, M., Preti, A., Meneghelli, A., & Cocchi, A. (2012) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2012.00351.x · Cited by 81
Polyunsaturated Fatty Acid Concentration Predicts Myelin Integrity in Early-Phase Psychosis
Peters, B. D., Machielsen, M. W. J., Hoen, W. P., Caan, M. W. A., Malhotra, A. K., Szeszko, P. R., Durán, M., Olabarriaga, S. D., & de Haan, L. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs089 · Cited by 83
Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta‐analysis
Carney, R., Cotter, J., Firth, J., Bradshaw, T., & Yung, A. R. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12699 · Cited by 79
Robinson, D. G., Gallego, J. A., John, M., Hanna, L. A., Zhang, J., Birnbaum, M. L., Greenberg, J., Naraine, M., Peters, B. D., McNamara, R. K., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.09.006 · Cited by 77
Sarris, J. J., Mischoulon, D., & Schweitzer, I. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00945.x · Cited by 78
van Zonneveld, S. M., van den Oever, E. J., Haarman, B. C. M., Grandjean, E. L., Nuninga, J. O., van de Rest, O., & Sommer, I. E. (2024) · Nutrients · doi:10.3390/nu16162646 · Cited by 88
Meta‐analysis of erythrocyte polyunsaturated fatty acid biostatus in bipolar disorder
McNamara, R. K., & Welge, J. A. (2016) · Bipolar Disorders · doi:10.1111/bdi.12386 · Cited by 80
Gama, C. S., Canever, L., Panizzutti, B., Gubert, C., Stertz, L., Massuda, R., Pedrini, M., de Lucena, D. F., Luca, R. D. D., Fraga, D. B., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.002 · Cited by 80
New drug developments in psychosis: Challenges, opportunities and strategies
Keshavan, M. S., Lawler, A. N., Nasrallah, H. A., & Tandon, R. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.07.004 · Cited by 79
Bukenaite, A., Štochl, J., Mossaheb, N., Schäfer, M. R., Klier, C. M., Becker, J., Schloegelhofer, M., Papageorgiou, K., Montejo, A. L., Russo, D. A., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.017 · Cited by 75
Self-citationOmega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia
Zugno, A. I., Chipindo, H. L., Volpato, A. M., Budni, J., Steckert, A. V., de Oliveira, M. B., Heylmann, A. S., Silveira, F. D. R., Mastella, G. A., Maravai, S. G., et al. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.11.049 · Cited by 76
Nelson, B., Amminger, G. P., Yuen, H. P., Wallis, N., Kerr, M., Dixon, L. B., Carter, C., Loewy, R. L., Niendam, T. A., Shumway, M., et al. (2017) · Early Intervention in Psychiatry · doi:10.1111/eip.12459 · Cited by 78
Self-citationGirgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 75
Microbiome in brain function and mental health
Kennedy, P. J., Murphy, A., Cryan, J. F., Ross, R. P., Dinan, T. G., & Stanton, C. (2016) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2016.05.001 · Cited by 81
Fusar-Poli, P., Frascarelli, M., Valmaggia, L., Byrne, M., Stahl, D., Rocchetti, M., Codjoe, L., Weinberg, L., Tognin, S., Xenaki, L., et al. (2015) · Psychological Medicine · doi:10.1017/s003329171400244x · Cited by 73
Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?
Bozzatello, P., Rocca, P., Mantelli, E., & Bellino, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215257 · Cited by 77
Sublette, M. E., Segal-Isaacson, C. J., Cooper, T. B., Fekri, S. M., Vanegas, N., Galfalvy, H., Oquendo, M. A., & Mann, J. J. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.10.007 · Cited by 77
Doaei, S., Bourbour, F., Teymoori, Z., Jafari, F., Kalantari, N., Torki, S. A., Ashoori, N., Gorgani, S. N., & Gholamalizadeh, M. (2021) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2020.101806 · Cited by 83
Emsley, R. A., Chiliza, B., Asmal, L., du Plessis, S., Phahladira, L. S., van Niekerk, E., van Rensburg, S. J., & Harvey, B. H. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.004 · Cited by 72
Amminger, G. P., Schäfer, M. R., Klier, C. M., Schlögelhofer, M., Mossaheb, N., Thompson, A. D., Bechdolf, A., Allott, K., McGorry, P. D., & Nelson, B. (2012) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2012.00362.x · Cited by 71
Self-citationInhibitory Interneurons, Oxidative Stress, and Schizophrenia
Sullivan, E. M., & O'Donnell, P. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs052 · Cited by 71
Strawn, J. R., Adler, C. M., McNamara, R. K., Welge, J. A., Bitter, S. M., Mills, N. P., Barzman, D. H., Cerullo, M. A., Chang, K. D., Strakowski, S. M., et al. (2014) · Bipolar Disorders · doi:10.1111/bdi.12113 · Cited by 70
N-3 Polyunsaturated Fatty Acids through the Lifespan: Implication for Psychopathology
Pusceddu, M. M., Kelly, P., Stanton, C., Cryan, J. F., & Dinan, T. G. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw078 · Cited by 70
Metadata
- Authors
- Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E.
- Affiliations
- Medical University of Vienna (AT)
- The University of Melbourne (AU)
- Clienia AG (CH)
- ORCID
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2010-02-01
- Volume
- 67
- Issue
- 2
- Pages
- 146
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2130372506
- Cited by
- 896
- References
- 45
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 29 · 2023: 22 · 2022: 20 · 2021: 51 · 2020: 42 · 2019: 59 · 2018: 33 · 2017: 52 · 2016: 69 · 2015: 82 · 2014: 95 · 2013: 85 · 2012: 98
- FWCI
- 92.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Stanley Medical Research Institute (03T-315)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- omega-3 polyunsaturated fatty acids, clinical high risk for psychosis, schizophrenia, adolescents and young adults, n-6/n-3 ratio, erythrocyte fatty acids, positive symptoms, negative symptoms, functional outcome, dietary supplementation, psychosis prevention, omega-3 deficiency
- MeSH terms
- Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Female, Health Status, Humans, Male, Patient Acceptance of Health Care, Psychotic Disorders, Risk Factors, Schizotypal Personality Disorder, Severity of Illness Index, Fatty Acids, Omega-3, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
